Navigation Links
Pittsburgh Life Sciences Greenhouse Announces the First Close of the PLSG Accelerator Fund LLC at $5 Million
Date:1/7/2011

PITTSBURGH, Jan. 7, 2011 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG), the organization providing capital investments and customized company formation and business growth programs to the region's life sciences enterprises, issued this statement through its President and Chief Executive Officer, John W. Manzetti announcing the first close of the PLSG Accelerator Fund, LLC (Accelerator Fund) at $5 million.

The Accelerator Fund is being managed by the PLSG to make venture investments in life sciences companies located in western Pennsylvania. The Fund is targeting total capital commitments of $10 million which will be committed during an investment period of up to five years. It is expected that investments will represent life sciences companies from several sectors including medical devices, diagnostics, therapeutics, healthcare information technology and biotechnology tools. The Accelerator Fund will invest in companies that already have been vetted by the PLSG, through investment due diligence and mentoring from the PLSG's Executive Program.

"The region needs a life sciences venture investor, and the PLSG Accelerator Fund is the only pure life sciences venture fund in the region," said John W. Manzetti, PLSG President & CEO. "We have formed this fund as part of our commitment to create long term sustainability for our portfolio companies and provide needed capital for growing companies while offering fund investors the best opportunity for returns."

About the Pittsburgh Life Sciences Greenhouse (PLSG)The Pittsburgh Life Sciences Greenhouse (PLSG) provides capital investments and customized company formation and business growth services to western Pennsylvania's life sciences enterprises; connects investors with their Investment Portfolio companies; expands established life sciences ventures; and relocates biomedical companies to Pennsylvania. The PLSG supports biosciences companies with promising innovations in: Biotechnology Tools, Diagnostics, Healthcare IT, Medical Devices and Therapeutics. Since 2002, PLSG has worked with 320 companies and has made direct investments of $16.3 M in 60 companies which has leveraged over $500M in additional capital to the region. In addition, PLSG has invested $15.2M as a limited partner in two Pennsylvania venture capital firms which in turn invest in technology companies in the Commonwealth. To see the full portfolio and more information about PLSG visit www.plsg.com.Editors Note:Structure Traditional VC Model LLC Management Member (PLSG)Term 10 years
'/>"/>

SOURCE Pittsburgh Life Sciences Greenhouse
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
2. The Pittsburgh Life Sciences Greenhouse Announces New Chairman of the Board
3. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
4. The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program
5. The Pittsburgh Life Sciences Greenhouse Invests $725K in Portfolio Companies
6. The Pittsburgh Life Sciences Greenhouse Adds Life Sciences Veterans to Executive Program
7. Pittsburgh Life Sciences Greenhouse Demonstrates a Regions Economic Resilience
8. The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum
9. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
10. NIH Awards Approximately $3M Grant for Research Involving WaferGens SmartChip(TM) Real-Time PCR System at the University of Pittsburgh
11. Opening Dedication of the New John G. Rangos Sr. Research Center at the New Childrens Hospital of Pittsburgh of UPMC Campus in Lawrenceville
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" ... in China , today announced that its board ... expiration date of the plan from March 27, 2017 to March ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, ... viscous and elastic characteristics when deformed, which is identical to how the human ... absorb compressive forces and return to its natural state along a hysteresis curve, ...
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
Breaking Biology Technology:
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... MELBOURNE , Australia , March ... clinical study data at the prestigious World Lung Imaging ... Dr. Andreas Fouras , was invited to deliver ... and pulmonary medicine. This globally recognised event brings together ... and share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):